FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939713994> ?p ?o ?g. }

• W2939713994 endingPage "14" @default.
• W2939713994 startingPage "S" @default.
• W2939713994 abstract "Breastfeeding MedicineVol. 14, No. S1 Biology and Science of Human MilkOpen AccessCreative Commons licenseBreast Milk Lipidomics: Insights to Infant Health Requirements and Targeted Strategies for the VulnerableCamilia R. MartinCamilia R. MartinAddress correspondence to: Camilia R. Martin, MD, MS, Department of Neonatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 E-mail Address: cmartin1@bidmc.harvard.eduDepartment of Neonatology, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Boston, Massachusetts.Search for more papers by this authorPublished Online:12 Apr 2019https://doi.org/10.1089/bfm.2019.0034AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Lipids are a complex and structurally diverse group of compounds that are essential for optimal growth, health, and development. Long-chain polyunsaturated fatty acids are selectively transferred from maternal circulation to the developing fetus in the third trimester. The shortened gestation of preterm infants can result in altered postnatal levels of fatty acids, such as decreases in docosahexaenoic acid (DHA) and arachidonic acid (AA) and concomitant increases in linoleic acid.1 These deficits in DHA and AA have been linked to late-onset sepsis and bronchopulmonary dysplasia (BPD), a type of chronic lung disease, in preterm infants. In a mouse model of BPD, treatment with downstream metabolites of DHA and AA that regulate inflammation and organogenesis was shown to reverse hyperoxia-induced lung injury, suggesting supplementation with these fatty acids or their metabolites may provide a novel therapeutic strategy for BPD.2 These studies emphasize the pleiotropic effects of fatty acids and that the fetal/preterm period is a unique time allowing one to tease out this pleiotropy and to determine the role of bioactive molecules in health and disease.Lipids are a major source of energy in breast milk, contributing 44% of the total energy intake in breastfed infants 1 month of age.3 Studies are starting to emerge about the lipid components of breast milk and how they relate to outcomes. A recent pilot study using liquid chromatography–mass spectrometry identified lipid biomarkers, such as medium-chain sphingomyelin, phospholipids containing dihomo-γ-linolenic acid (DGLA) and DHA, and DGLA-derived oxylipin, in breast milk that displayed a good ability to predict weight gain during the hospital stay in preterm infants.4 Plasmalogens, a type of glycerophospholipid, are also found in breast milk and have been linked to disease outcomes. Higher levels of plasmalogens and polyunsaturated fatty acids have been associated with reduced risk of BPD in preterm infants,5 and preliminary results from a current study on the breast milk lipidome seem to support these findings. Plasmalogens are also one of the main classes of lipids present in the developing cerebrum, cerebellum, and brainstem, indicating that they are important for brain development.6 Of note, lower levels of plasmalogens have been reported in patients with Alzheimer's disease but not in patients with other neurodegenerative disorders, suggesting plasmalogen deficiency may be a specific biomarker for Alzheimer's disease.7,8Lipids in breast milk are contained within milk fat globules, which consist of a trilayer membrane of polar lipids, cholesterol, enzymes, and glycoproteins surrounding a triglyceride core.9 A study in rats demonstrated that formula supplemented with bovine milk fat globule membrane (MFGM) normalized intestinal development compared with control formula, with intestinal readouts similar to rats receiving mothers' milk.10 MFGM supplementation also altered the gut microbiota, resulting in a microbiome at the phylum level resembling that found in pups receiving mothers' milk. Microbial species richness and evenness were similar in pups receiving MFGM formula or mothers' milk; however, there were significant differences in diversity at lower taxonomic levels across all groups. Studies assessing the benefits of MFGM supplementation in infants and children have shown positive, but modest, effects on neurodevelopment and gut health.11 A randomized controlled trial in healthy term infants reported higher cognitive scores at 12 months using the Bayley Scales of Infant and Toddler Development in infants fed a low-energy and low-protein formula supplemented with MFGM versus those fed a standard formula.12 A separate randomized controlled trial comparing MFGM formula with standard formula in infants showed significant differences in the plasma and erythrocyte membrane lipidomes at 6 months and the serum lipidome at 4 months, suggesting changes in the lipidome may contribute to the beneficial effects reported in infants receiving MFGM.13 MFGM supplementation may also have beneficial effects in adult populations. Adults randomized to receive milk enriched with MFGM twice daily showed improved resistance to diarrheagenic Escherichia coli compared with controls, providing evidence that MFGM may affect resistance to infection.14Although initial studies suggest MFGM supplementation may induce system-level changes, the effects are modest and further studies are needed to confirm long-term benefits. Understanding the structure and function of MFGM may offer insights into the optimal lipid composition and delivery system needed to support health and development across the life span. The unique properties of MFGM may also offer insights into natural drug delivery platforms for the targeted treatment of various disorders, such as cancer, mucosal injury, and neurodegenerative disorders.Disclosure StatementC.R.M. is a consultant to Prolacta, Fresenius-Kabi, and Alcresta. C.R.M. has research grant support from Alcresta and Abbott Nutrition.References1. Martin CR, Dasilva DA, Cluette-Brown JE, et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr 2011;159:743–749.e1–e2. Crossref, Medline, Google Scholar2. Martin CR, Zaman MM, Gilkey C, et al. Resolvin D1 and lipoxin A4 improve alveolarization and normalize septal wall thickness in a neonatal murine model of hyperoxia-induced lung injury. PLoS One 2014;9:e98773. Crossref, Medline, Google Scholar3. Koletzko B. Human milk lipids. Ann Nutr Metab 2016;69:28–40. Crossref, Medline, Google Scholar4. Alexandre-Gouabau MC, Moyon T, Cariou V, et al. Breast milk lipidome is associated with early growth trajectory in preterm infants. Nutrients 2018;10:pii: E164. Crossref, Medline, Google Scholar5. Rüdiger M, von Baehr A, Haupt R, et al. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 2000;28:1572–1577. Crossref, Medline, Google Scholar6. Martínez M. Myelin lipids in the developing cerebrum, cerebellum, and brain stem of normal and undernourished children. J Neurochem 1982;39:1684–1692. Crossref, Medline, Google Scholar7. Wood PL, Mankidy R, Ritchie S, et al. Circulating plasmalogen levels and Alzheimer disease assessment scale–cognitive scores in Alzheimer patients. J Psychiatry Neurosci 2010;35:59–62. Crossref, Medline, Google Scholar8. Fujino T, Yamada T, Asada T, et al. Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer's disease and mild cognitive impairment: A multicenter, randomized, double-blind, placebo-controlled trial. EBioMedicine 2017;17:199–205. Crossref, Medline, Google Scholar9. Lopez C, Ménard O. Human milk fat globules: Polar lipid composition and in situ structural investigations revealing the heterogeneous distribution of proteins and the lateral segregation of sphingomyelin in the biological membrane. Colloids Surf B Biointerfaces 2011;83:29–41. Crossref, Medline, Google Scholar10. Bhinder G, Allaire JM, Garcia C, et al. Milk fat globule membrane supplementation in formula modulates the neonatal gut microbiome and normalizes intestinal development. Sci Rep 2017;7:45274. Crossref, Medline, Google Scholar11. Hernell O, Timby N, Domellöf M, et al. Clinical benefits of milk fat globule membranes for infants and children. J Pediatr 2016;173 Suppl:S60–S65. Crossref, Medline, Google Scholar12. Timby N, Domellöf E, Hernell O, et al. Neurodevelopment, nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula supplemented with bovine milk fat globule membranes: A randomized controlled trial. Am J Clin Nutr 2014;99:860–868. Crossref, Medline, Google Scholar13. Grip T, Dyrlund TS, Ahonen L, et al. Serum, plasma and erythrocyte membrane lipidomes in infants fed formula supplemented with bovine milk fat globule membranes. Pediatr Res 2018;84:726–732. Crossref, Medline, Google Scholar14. Ten Bruggencate SJ, Frederiksen PD, Pedersen SM, et al. Dietary milk-fat-globule membrane affects resistance to diarrheagenic Escherichia coli in healthy adults in a randomized, placebo-controlled, double-blind study. J Nutr 2016;146:249–255. Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited byNutrition in Clinical Practice, Vol. 35, No. 1 Volume 14Issue S1Apr 2019 Information© Camilia R. Martin, 2019; Published by Mary Ann Liebert, Inc.To cite this article:Camilia R. Martin.Breast Milk Lipidomics: Insights to Infant Health Requirements and Targeted Strategies for the Vulnerable.Breastfeeding Medicine.Apr 2019.S-13-S-14.http://doi.org/10.1089/bfm.2019.0034creative commons licensePublished in Volume: 14 Issue S1: April 12, 2019Keywordshuman milkDHAarachidonic acidOpen accessThis Open Access article is distributed under the terms of the Creative Commons License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.PDF download" @default.
• W2939713994 created "2019-04-25" @default.
• W2939713994 creator A5053932882 @default.
• W2939713994 date "2019-04-01" @default.
• W2939713994 modified "2023-10-02" @default.
• W2939713994 title "Breast Milk Lipidomics: Insights to Infant Health Requirements and Targeted Strategies for the Vulnerable" @default.
• W2939713994 cites W1998991733 @default.
• W2939713994 cites W2042459131 @default.
• W2939713994 cites W2052088120 @default.
• W2939713994 cites W2057657006 @default.
• W2939713994 cites W2117388188 @default.
• W2939713994 cites W2130058457 @default.
• W2939713994 cites W2159972202 @default.
• W2939713994 cites W2271567802 @default.
• W2939713994 cites W2396986241 @default.
• W2939713994 cites W2571897146 @default.
• W2939713994 cites W2591489876 @default.
• W2939713994 cites W2602978633 @default.
• W2939713994 cites W2771465282 @default.
• W2939713994 cites W2885278523 @default.
• W2939713994 doi "https://doi.org/10.1089/bfm.2019.0034" @default.
• W2939713994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30985208" @default.
• W2939713994 hasPublicationYear "2019" @default.
• W2939713994 type Work @default.
• W2939713994 sameAs 2939713994 @default.
• W2939713994 citedByCount "1" @default.
• W2939713994 countsByYear W29397139942019 @default.
• W2939713994 crossrefType "journal-article" @default.
• W2939713994 hasAuthorship W2939713994A5053932882 @default.
• W2939713994 hasBestOaLocation W29397139941 @default.
• W2939713994 hasConcept C185592680 @default.
• W2939713994 hasConcept C187212893 @default.
• W2939713994 hasConcept C2775871700 @default.
• W2939713994 hasConcept C2776283161 @default.
• W2939713994 hasConcept C2779150110 @default.
• W2939713994 hasConcept C3020294031 @default.
• W2939713994 hasConcept C55493867 @default.
• W2939713994 hasConcept C58017582 @default.
• W2939713994 hasConcept C60644358 @default.
• W2939713994 hasConcept C71924100 @default.
• W2939713994 hasConcept C86803240 @default.
• W2939713994 hasConcept C99454951 @default.
• W2939713994 hasConceptScore W2939713994C185592680 @default.
• W2939713994 hasConceptScore W2939713994C187212893 @default.
• W2939713994 hasConceptScore W2939713994C2775871700 @default.
• W2939713994 hasConceptScore W2939713994C2776283161 @default.
• W2939713994 hasConceptScore W2939713994C2779150110 @default.
• W2939713994 hasConceptScore W2939713994C3020294031 @default.
• W2939713994 hasConceptScore W2939713994C55493867 @default.
• W2939713994 hasConceptScore W2939713994C58017582 @default.
• W2939713994 hasConceptScore W2939713994C60644358 @default.
• W2939713994 hasConceptScore W2939713994C71924100 @default.
• W2939713994 hasConceptScore W2939713994C86803240 @default.
• W2939713994 hasConceptScore W2939713994C99454951 @default.
• W2939713994 hasIssue "S1" @default.
• W2939713994 hasLocation W29397139941 @default.
• W2939713994 hasLocation W29397139942 @default.
• W2939713994 hasOpenAccess W2939713994 @default.
• W2939713994 hasPrimaryLocation W29397139941 @default.
• W2939713994 hasRelatedWork W127410354 @default.
• W2939713994 hasRelatedWork W2003185770 @default.
• W2939713994 hasRelatedWork W2052775886 @default.
• W2939713994 hasRelatedWork W2081889687 @default.
• W2939713994 hasRelatedWork W2350379238 @default.
• W2939713994 hasRelatedWork W2417957759 @default.
• W2939713994 hasRelatedWork W2891803556 @default.
• W2939713994 hasRelatedWork W2908246486 @default.
• W2939713994 hasRelatedWork W3082099351 @default.
• W2939713994 hasRelatedWork W4214527551 @default.
• W2939713994 hasVolume "14" @default.
• W2939713994 isParatext "false" @default.
• W2939713994 isRetracted "false" @default.
• W2939713994 magId "2939713994" @default.
• W2939713994 workType "article" @default.